|
Global annual spending on cancer drugs has hit $100bn for the first time as the pharmaceuticals industry prepares to launch a fresh generation of treatments that promise to push costs even higher. 全球用于癌症药物的年度开支首次达到1000亿美元大关。与此同时，制药产业正准备推出新一代癌症治疗方案，这些治疗方案势必进一步推升治疗成本。 The record 2017 figure marks a 10 per cent increase from a year earlier, largely because of rising drug prices and increased incidence of cancer. 比起前一年，2017年这一创纪录的开支增长了10%。在很大程度上，这一增幅是药品价格攀升及癌症发病率增加导致的。 The data, from the IMS Institute for Healthcare Informatics, a respected US research organisation, comes at a time of growing excitement among medics and investors over new cancer drugs heralded as the biggest step forward in oncology for decades. 该数据由著名的美国研究机构艾美仕医疗保健信息研究所(IMS Institute for Healthcare Informatics)发布。就在艾美仕发布这一数据之际，越来越多的医生及投资者正在为新的癌症药物欢欣鼓舞。这批新的药物被誉为肿瘤医学界数十年来的最大进展。 Merck & Co, Bristol-Myers Squibb, Roche and AstraZeneca are among those developing so-called cancer immunotherapies that harness the body’s immune system to fight tumours. | 
